Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524518 | NSE Symbol : KREBSBIO | ISIN : INE268B01013 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
07-May-2025	20-May-2025	Accounts	Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve to consider and approved audited financial results for 4th quarter and year ended 31.03.2025 Outcome of Board Meeting held on 20.05.2025 (As Per BSE Announcement Dated on: 20.05.2025)
15-Jan-2025	04-Feb-2025	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve The Company has enclosing herewith prior intimation of the Board Meeting to be held on 4th February 2024 Outcome of Board Meeting held on 04.02.2025 (As Per BSE Announcement dated on 04.02.2025)
28-Oct-2024	11-Nov-2024	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve Intimation of Board Meeting to be held on 11th November 2024 Outcome of Board Metting (As Per BSE Announcement Dated on 11.11.2024)
19-Jul-2024	07-Aug-2024	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve The Company has informed that the meeting of Board of Directors of the Company is schedule on 07/08/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2024. Outcome of Board Meeting dated 07.08.2024 (As Per BSE Announcement dated on 07.08.2024)
08-May-2024	21-May-2024	Accounts	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve Audited Financial Results for the 4th quarter and financial year ended 31st March 2024. Outcome of Board Meeting dated 21.05.2024 Financial Results for the year ended 31.03.2024 Appointment of Company Secretary (As Per BSE Announcement Dated on 21/05/2024)
19-Jan-2024	12-Feb-2024	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve Unaudited Financial Results of the 3rd quarter and 9 months ended December 31 2023 of the Financial year 2023-24. we are enclosing herewith Unaudited Financial Results of the Company along with limited review report issued by the Statutory Auditors of the Company for 3rd Quarter and 9 month ended 31st December 2023 which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai. Please find enclosed herewith Unaudited Financial Results for 3rd Quarter and 9 Months ended 31st December 2023. Outcome of Board Meeting held on 12 February 2024. (As Per BSE Announcement Dated on 12/02/2024)
17-Jan-2024	17-Jan-2024	Change in Other Executives	The Board of Directors of the Company in its meeting held today and on recommendation of Nomination and Remuneration Committee have considered and approved the appointment of Mr. Keyur Doshi (Membership Number: A32107) as Company Secretary, Compliance Officer & Key Managerial Personnel of the Company with effect from 17th January 2024.
18-Oct-2023	08-Nov-2023	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve un-audited financial results for the quarter and half year ended September 30 2023. Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2023 (As Per BSE Announcement dated on 08.11.2023)
21-Jul-2023	09-Aug-2023	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 inter alia to consider and approve the un-audited financial results for the 1st quarter ended 30th June 2023. Outcome of Board Meeting - Unaudited Financial Results of the Company for the 1st Quarter ended June 30, 2023 (As Per BSE Announcement Dated on 09.08.2023)
11-May-2023	24-May-2023	Accounts	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve Audited Financial Results for the 4th quarter and financial year ended 31st March 2023. Further with reference to the above meeting of the Board of Directors we have already informed vide our letter dated 31st March 2023 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations 2015 shall remain closed with effect from closure of business hours on 31st March 2023 and until 48 hours after the declaration of the Companys audited financial results for the 4th quarter and financial year ended 31st March 2023 i.e. 26th May 2023. Further to our letter dated May 11, 2023 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today have approved the following: 1. Audited Financial Results of the Company for the quarter and financial year ended March 31, 2023 along with the Audit Report by the Statutory Auditors thereon - Enclosed. 2. Declaration in respect of Audit Report on the Financial Statement for the financial year ended March 31, 2023 with unmodified opinion from MD & CFO. The Meeting of the Board of Directors commenced at 12:30 pm and concluded at 3:45 p.m. The above is for your information and record. (As Per BSE Announcement dated on 24.05.2023)
23-Jan-2023	03-Feb-2023	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 47 of the SEBI (LODR) Regulations 2015 notice is hereby given that meeting of the Board of Directors of the Company will be held on Friday February 03 2023 inter-alia to consider and adopt the Unaudited Financial Results for the 3rd quarter and nine months ended December 31 2022 of the Financial year 2022-23. Further with reference to the above meeting of the Board of Directors we have already informed vide our letter dated December 26 2022 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations 2015 shall remain closed w.e.f December 31 2022 and until 48 hours after the declaration of the Companys unaudited financial results for the 3rd quarter and nine months ended December 31 2022 i.e. February 5 2023. Resignation of Mr. Ravi Babu as Chief Financial Officer and Key Managerial Personnel of the Company from the closure of business hours on February 3, 2023. Details of the resigned CFO is as below: Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the CFO appointed Appointment of Mr. Rohit Taparia as Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the Company Secretary appointed. Further to our letter dated January 23, 2023 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today have approved the agenda item as per the attached file. The Meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 03:20 p.m. Appointment of Mr. Rohit Taparia as Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the Company Secretary appointed. Revised outcome with Digital Signature - Further to our letter dated January 23, 2023 and in compliance with Regulation 30 read with Schedule Ill and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today have approved the agenda as attached. Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report by the Statutory Auditors thereon. Filing of Resignation of Mr. Ravi Babu as Chief Financial Officer and Key Managerial Personnel of the Company from the closure of business hours on February 3, 2023 with Digital Signature. Details enclosed as per attached file. Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report by the Statutory Auditors thereon Revised intimation of Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effective from February 3, 2023 wit Digital Signature. Enclosed is details of the CFO appointed in the attached file. (As Per BSE Announcement dated on 03.02.2023)
02-Nov-2022	10-Nov-2022	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve Unaudited Financial Results for the 2nd quarter and half-year ended September 30 2022 of the Financial year 2022-23. Q2FY23 Results (As per BSE Announcement Dated on 10/11/2022)
26-Jul-2022	01-Aug-2022	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2022 inter alia to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Monday 1st August 2022 to transact inter alia the following: 1. To consider and approve the un-audited financial results along with the Limited review Report for the quarter ended 30th June 2022. 2. Any other matter with the permission of the Chair. We wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 1st August, 2022: (a) The un-audited financial results for the quarter ended 30th June, 2022 along with the Auditor's Limited Review Report thereon (Enclosed herewith) have been adopted by the Board. (b) The Board has taken note of the Resignation email of Ms.Taruni Banda, Company Secretary and Compliance officer dated June 27th, 2022, has accepted/approved the Resignation and relieved her from all responsibilities w.e.f 6th August, 2022. (c) The Board report and annexures have been approved for the 30th Annual General meeting. (As Per BSE Announcement Dated on 01.08.2022)
13-May-2022	23-May-2022	Accounts	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 inter alia to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Monday 23rd May 2022 to transact inter alia the following: 1. To consider and approve the audited financial results along with the Auditor Report for the quarter and year ended 31st March 2022. 2. Any other matter with the permission of the Chair. We wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 23rd May, 2022: (a) The audited financial results for the quarter and Year ended 31st March, 2022 along with the Auditor's Report thereon have been adopted by the Board. We herewith submit to the Exchange the quick results for the quarter and year ended 31st March, 2022 along with the Auditor Report thereon (Enclosed herewith) as approved by the Board of Directors at their meeting held on 23rd May, 2022. (As Per BSE Announcement dated on 23.05.2022)
05-Feb-2022	12-Feb-2022	Quarterly Results	KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 inter alia to consider and approve We refer to the above-mentioned subject we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Saturday 12th February 2022 to transact inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and Nine months ended 31st December 2021. 2. Any other matter with the permission of the Chair. Further in connection to the above trading window for dealing in shares of the Company was closed for the designated persons connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations 2015 as amended from 1st January 2022 and shall re-open 48 hours after the declaration of results. The Board of Directors in their meeting held on 12th February, 2022 have inter alia considered and approved the unaudited financial results for the quarter and nine months ended 31st December, 2021 and taken on record the limited review report issued by the Statutory Auditors of the Company Unaudited financial results as approved by the Board of Directors for the quarter and three months ended 31st December, 2021 along with limited review report given by the Statutory Auditors (As Per BSE Announcement Dated on 12.02.2022) Pursuant to Regulation 30 read with Schedule III Part A Para A of SEBI Listing Regulations, we are herewith enclosing the copies of newspaper advertisement published in Financial Express (English) and Praja Shakti (Telugu), relating to the unaudited financial results for the quarter and nine months ended 31st December 2021 approved by the Board of Directors in their meeting held on 12th February 2022 through Video Conferencing. (As Per BSE Announcement dated on 15.02.2022)

1 2

LOGIN HERE

Krebs Biochemicals & Industries Ltd

Board Meeting